Lee, David S.
Travis, Emma Y.
Wong, Susan K.
Munyemana, Marie-Ange
Mueller, Lauren
Rowling, Cathryn Collopy
Rich, Jason T.
Pipkorn, Patrik
Puram, Sidharth V.
Jackson, Ryan S.
Adkins, Douglas R.
Oppelt, Peter
Thorstad, Wade L.
Wick, Cameron C.
Zevallos, Jose P.
McClannahan, Kate
Mazul, Angela L.
Funding for this research was provided by:
National Institute of Deafness and Other Communication Disorders (T32DC000022, R25DC020706)
Article History
Received: 3 February 2024
Accepted: 2 April 2024
First Online: 17 April 2024
Declarations
:
: David S. Lee, none. Emma Y. Travis, none. Susan K. Wong, none. Marie-Ange Munyemana, none. Lauren Mueller, none. Cathryn Collopy Rowling, none. Amanda J. Ortman, none. Jason T. Rich, none. Patrik Pipkorn, none. Sidharth V. Puram, none. Ryan S. Jackson, none. Douglas R. Adkins: research grant, Merck, Cue Biopharma, Hookipa Pharma, Blueprint Medicine, Exelixis, Kura, Vaccinex, Pfizer, Eli Lilly, Celgene/BMS, Novartis, AstraZeneca, Atara Bio, Aduro, Sensei, Matrix Biomed, ISA, Debiopharm, Epizyme, Shanghai De Novo, Roche, Gilead, Rubius; advisory board: Merck, Cue Biopharma, Blueprint Medicine, Exelixis, Kura, TwoX. Peter Oppelt, none. Wade L. Thorstad, employee: Elekta, Inc. Cameron C. Wick, consultant: Stryker and Cochlear Ltd. Jose Zevallos; advisory board: Summit Biolabs; Scientific Founder and Chair of the Board: Summit Biolabs; Droplet Biosciences. Kate McClannahan, none. Angela L. Mazul, none.
: The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH.